BRAINSTORM CELL THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Condensed Consolidated Statements of Comprehensive Loss
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three months ended | ||||||
| · · March 31, | ||||||
| · 2024 · 2023 | ||||||
| · · Unaudited | ||||||
| Operating expenses: | | | ||||
| | | | | | | |
| Research and development, net | | $961 | | $2,924 | ||
| General and administrative | | 1,513 | | 2,227 | ||
| | | | | | | |
| Operating loss | | (2,474) | | (5,151) | ||
| | | | | | | |
| Financial income, net | | | 13 | | | 92 |
| | | | | | | |
| Loss on change in fair value of Warrants liability (Note 6) | | (940) | | — | ||
| | | | | | | |
| Net loss | | $(3,401) | | $(5,059) | ||
| | | | | | | |
| Basic and diluted net loss per share from continuing operations | | $(0.05) | | $(0.14) | ||
| | | | | | | |
| Weighted average number of shares outstanding used in computing basic and diluted net loss per share | | 64,738,544 | | 36,735,435 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.